Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06353022
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-08
First Post:
2024-03-22
Brief Title:
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab Bortezomib Lenalidomide and Dexamethasone D-VRd in Newly Diagnosed Multiple Myeloma
Sponsor:
Organization:
Nantes University Hospital